Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib monotherapy in moderate to severe atopic dermatitis
NCT03334396Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of baricitinib in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Nov 2017; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03334396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334396.